Coming into focus: The nonovarian origins of ovarian cancer

Annals of Oncology

Volumn 24, Issue SUPPL.B, 2013, Pages

  Dubeau, L ^a   Drapkin, R ^b,c  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Coelomic epithelium; Extrauterine M llerian epithelium; Fallopian tube fimbriae; Ovarian carcinoma; Primary peritoneal carcinoma

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN;

ARTICLE; CANCER GRADING; CANCER RISK; CARCINOGENESIS; CLEAR CELL CARCINOMA; COLLOID CARCINOMA; CYSTADENOMA; ENDOMETRIOID CARCINOMA; ENDOMETRIOSIS; EPITHELIUM CELL; EPITHELIUM TUMOR; ESTRUS CYCLE; GENE MUTATION; GENETIC PREDISPOSITION; HUMAN; MENSTRUAL CYCLE; METAPLASIA; MOUSE MODEL; MUELLERIAN DUCT; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; SALPINGOOOPHORECTOMY; TUMOR MODEL; UTERINE TUBE;

COELOMIC EPITHELIUM; EXTRAUTERINE MÜLLERIAN EPITHELIUM; FALLOPIAN TUBE FIMBRIAE; OVARIAN CARCINOMA; PRIMARY PERITONEAL CARCINOMA;

BRCA1 PROTEIN; BRCA2 PROTEIN; CARCINOGENESIS; CYSTADENOCARCINOMA, SEROUS; EPITHELIAL CELLS; FALLOPIAN TUBES; FEMALE; FIMBRIAE, BACTERIAL; HUMANS; MULLERIAN DUCTS; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS;

EID: 84886285788     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt308     Document Type: Article

References (73)

1. Boyle P, Levin B. World cancer report 2008. Geneva, Switzerland: WHO Press, 2008.
2. Orthmann EG. Ein primãres carcinoma papillare tubae dextrae, verbunden mit ovarial-abscess. Centrabl f Gynãk 1886; 10: 816-818.
3. Finn WF, Javert CT. Primary and metastatic cancer of the fallopian tube. Cancer 1949; 2: 803-814.
4. Roberts DK, Marshall RB, Wharton JT. Ultrastructure of ovarian tumors. I. Papillary serous cystadenocarcinoma. Cancer 1970; 25: 947-958.
5. Scully RE. Pathology of ovarian cancer precursors. J Cell Biochem Suppl 1995; 23: 208-218.
6. Pentheroudakis G, Pavlidis N. Serous papillary peritoneal carcinoma: unknown primary tumour, ovarian cancer counterpart or a distinct entity? A systematic review. Crit Rev Hematol/Oncol 2010; 75: 27-42.
7. Auersperg N, Maines-Bandiera SL, Dyck H. Ovarian carcinogenesis and the biology of the ovarian surface epithelium. J Cell Physiol 1997; 173: 261-265.
8. Hertig AT, Gore H. Ovarian cystomas of germinal epithelial origin-a histogenetic classification. Rocky Mt Med J 1958; 55: 47-50.
9. Wong AST, Auersperg N. Ovarian surface epithelium: family history and early events in ovarian cancer. Reprod Biol Endocrinol 2003; 1: 1-8.
10. Auersperg N, Gilks CB. The origin of ovarian cancer: a developmental view. Gynecol Oncol 2008; 110: 452-454.
11. Guioli S, Sekido R, Lovell-Badge R. The origin of the Mullerian duct in chick and mouse. Dev Biol 2007; 302: 389-398.
12. Orvis GD, Behringer RR. Cellular mechanisms of Mullerian duct formation in the mouse. Dev Biol 2007; 306: 493-504.
13. Salazar H, Godwin AK, Daly MB et al. Microscopic benign and invasive malignant neoplasms and a cancer-prone phenotype in prophylactic oophorectomies. J Natl Cancer Inst 1996; 88: 64-67.
14. Werness BA, Afify AM, Bielat KL et al. Altered surface and cyst epithelium of ovaries removed prophylactically from women with a family history of ovarian cancer. Hum Pathol 1999; 30: 151-157.
15. Callahan MJ, Crum CP, Medeiros F et al. Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction. J Clin Oncol 2007; 25: 3985-3990.
16. Colgan TJ, Murphy J, Cole DE et al. Occult carcinoma in prophylactic oophorectomy specimens: prevalence and association with BRCA germline mutation status. Am J Surg Pathol 2001; 25: 1283-1289.
17. Kindelberger DW, Lee Y, Miron A et al. Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: evidence for a causal relationship. Am J Surg Pathol 2007; 31: 161-169.
18. Kuhn E, Kurman RJ, Vang R et al. TP53 mutations in serous tubal intraepithelial carcinoma and concurrent pelvic high-grade serous carcinoma-evidence supporting the clonal relationship of the two lesions. J Pathol 2012; 226: 421-426.
19. Leeper K, Garcia R, Swisher E et al. Pathologic findings in prophylactic oophorectomy specimens in high-risk women. Gynecol Oncol 2002; 87: 52-56.
20. Medeiros F, Muto MG, Lee Y et al. The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome. Am J Surg Pathol 2006; 30: 230-236.
21. Piek JM, van Diest PJ, Zweemer RP et al. Dysplastic changes in prophylactically removed Fallopian tubes of women predisposed to developing ovarian cancer. J Pathol 2001; 195: 451-456.
22. Przybycin CG, Kurman RJ, Ronnett BM et al. Are all pelvic (nonuterine) serous carcinomas of tubal origin. Am J Surg Pathol 2010; 34: 1407-1416.
23. Tone AA, Salvado S, Finlayson SJ et al. The role of the fallopian tube in ovarian cancer. Clin Adv Hematol Oncol 2012; 10: 296-306.
24. Tonin P, Weber B, Offit K et al. Frequency of recurrent BRCA1 and BRCA2 mutations in 222 Ashkenazi Jewish breast cancer families. Nat Med 1996; 2: 1179-1183.
25. Crum CP, Drapkin R, Miron A et al. The distal fallopian tube: a new model for pelvic serous carcinogenesis. Curr Opin Obstet Gynecol 2007; 19: 3-9.
26. Kwon JS, Tinker A, Pansegrau G et al. Prophylactic salpingectomy and delayed oophorectomy as an alternative for BRCA mutation carriers. Obstet Gynecol 2013; 121: 14-24.
27. Finch A, Beiner M, Lubinski J et al. Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation. JAMA 2006; 296: 185-192.
28. Levine DA, Argenta PA, Yee CJ et al. Fallopian tube and primary peritoneal carcinomas associated with BRCA mutations. J Clin Oncol 2003; 21: 4222-4227.
29. Olivier RI, van Beurden M, Lubsen MAC et al. Clinical outcome of prophylactic oophorectomy in BRCA1/BRCA2 mutation carriers and events during follow-up. Br J Cancer 2004; 90: 1492-1497.
30. Kurman RJ, Vang R, Junge J et al. Papillary tubal hyperplasia: the putative precursor of ovarian atypical proliferative (borderline) serous tumors, noninvasive implants, and endosalpingiosis. Am J Surg Pathol 2011; 35: 1605-1614.
31. Laury AR, Ning G, Quick CM et al. Fallopian tube correlates of ovarian serous borderline tumors. Am J Surg Pathol 2011; 35: 1759-1765.
32. Li J, Abushahin N, Pang S et al. Tubal origin of 'ovarian' low-grade serous carcinoma. Modern Pathol 2011; 24: 1488-1499.
33. Kurman RJ, Hedrick Ellenson L, Ronnett BM. Blaustein's Pathology of the Female Genital Tract. New York: Springer 2011.
34. Lauchlan SC. The secondary mullerian system revisited. Int J Gynecol Pathol 1994; 13: 73-79.
35. Dubeau L. The cell of origin of ovarian epithelial tumors. Lancet Oncol 2008; 9: 1191-1197.
36. Alvarez AA, Moore WF, Robboy SJ et al. K-ras mutations in Mullerian inclusion cysts associated with serous borderline tumors of the ovary. Gynecol Oncol 2001; 80: 201-206.
37. Carrick KS, Milvenan JS, Albores-Saavedra J. Serous tumor of low malignant potential arising in inguinal endosalpingiosis: report of a case. Int J Gynecol Pathol 2003; 22: 412-415.
38. Chandraratnam E, Leong AS-Y. Papillary serous cystadenoma of borderline malignancy arising in a paraovarian paramesonephric cyst. Light microscopic and ultrastructural observations. Histopathology 1982; 7: 601-611.
39. Kadar N, Krumerman M. Possible metaplastic origin of lymph node "metastases" in serous ovarian tumor of low malignant potential (borderline serous tumor). Gynecol Oncol 1995; 59: 394-397.
40. McCluggage WG, O'Rourke D, McElhenney C et al. Mullerian papilloma-like proliferation arising in cystic pelvic endosalpingiosis. Hum Pathol 2002; 33: 944-946.
41. Prade M, Spatz A, Bentley R et al. Borderline and malignant serous tumor arising in pelvic lymph nodes: evidence of origin in benign glandular inclusions. Int J Gynecol Pathol 1995; 14: 87-91.
42. Kruk PA, Maines-Bandiera SL, Auersperg N. A simplified method to culture human ovarian surface epithelium. Lab Invest 1990; 63: 132-136.
43. Clark-Knowles KV, Garson K, Jonkers J et al. Conditional inactivation of Brca1 in the mouse ovarian surface epithelium results in an increase in preneoplastic changes. Exp Cell Res 2007; 313: 133-145.
44. Connolly DC, Bao R, Nikitin AY et al. Female mice chimeric for expression of the simian virus 40 TAg under control of the MISIIR promoter develop epithelial ovarian cancer. Cancer Res 2003; 63: 1389-1397.
45. Dinulescu DM, Ince TA, Quade BJ et al. Role of K-ras and Pten in the development of mouse models of endometriosis and endometrioid ovarian cancer. Nat Med 2005; 11: 63-70.
46. Nikitin AF, Choi K-C, Eng JP et al. Induction of carcinogenesis by concurrent inactivation of p53 and Rb1 in the mouse ovarian surface epithelium. Cancer Res 2003; 63: 3459-3463.
47. Orsulic S, Li Y, Soslow RA et al. Induction of ovarian cancer by defined multiple genetic changes in a mouse model system. Cancer Cell 2002; 1: 53-62.
48. Szabova L, Yin C, Bupp S et al. Perturbation of Rb, p53, and Brca1 or Brca2 cooperate in inducing metastatic serous epithelial ovarian cancer. Cancer Res 2012; 72: 4141-4153.
49. Wu R, Hendrix-Lucas N, Kuick R et al. Mouse model of human ovarian endometrioid adenocarcinoma based on somatic defects in the Wnt/b-catenin and PI3 K/Pten signaling pathways. Cancer Cell 2007; 11: 321-333.
50. Laury AR, Perets R, Piao H et al. A comprehensive analysis of PAX8 expression in human epithelial tumors. Am J Surg Pathol 2011; 35: 816-826.
51. Tone AA, Begley H, Sharma M et al. Gene expression profiles of luteal phase fallopian tube epithelium from BRCA mutation carriers resemble high-grade serous carcinoma. Clin Cancer Res 2008; 14: 4067-4078.
52. Jazaeri AA, Bryant JL, Park H et al. Molecular requirements for transformation of fallopian tube epithelial cells into serous carcinoma. Neoplasia 2011; 13: 899-991.
53. Karst AM, Drapkin R. The new face of ovarian cancer modeling: better prospects for detection and treatment. F1000 Med Reprod 2011; 3: 22.
54. Karst AM, Levanon K, Drapkin R. Modeling high-grade serous ovarian carcinogenesis from the fallopian tube. Proc Natl Acad Sci USA 2011; 108: 7547-7552.
55. Shan W, Mercado-Uribe I, Zhang J et al. Mucinous adenocarcinoma developed from human fallopian tube epithelial cells through defined genetic modifications. Cell Cycle 2012; 11: 2107-2113.
56. Bowen NJ, Logani S, Dickerson EB et al. Emerging roles for PAX8 in ovarian cancer and endosalpingeal development. Gynecol Oncol 2007; 104: 331-337.
57. Mittag J, Winterhager E, Bauer K et al. Congential hypothyroid female Pax8- deficient mice are infertile despite thyroid hormone replacement therapy. Endocrinology 2007; 148: 719-725.
58. King SM, Hilliard TS, Wu LY et al. The impact of ovulation on fallopian tube epithelial cells: evaluating three hypotheses connecting ovulation and serous ovarian cancer. Endocr Relat Cancer 2011; 18: 627-642.
59. Fathalla MF. Incessant ovulation-a factor in ovarian neoplasia? Lancet Oncol 1971; 2: 163.
60. Fotheringham S, Levanon K, Drapkin R. Ex vivo culture of primary human fallopian tube epithelial cells. J Vis Exp 2011; 9: 51.
61. Levanon K, Ng V, Piao HY et al. Primary ex vivo cultures of human fallopian tube epithelium as a model for serous ovarian carcinogenesis. Oncogene 2010; 29: 1103-1113.
62. Miessen K, Sharbati S, Einspanier R et al. Modelling the porcine oviduct epithelium: a polarized in vitro system suitable for long-term cultivation. Theriogenology 2011; 76: 900-910.
63. Lee Y, Miron A, Drapkin R et al. A candidate precursor to serous carcinoma that originates in the distal fallopian tube. J Pathol 2007; 211: 26-35.
64. Luo MP, Gomperts B, Imren S et al. Establishment of long-term in vitro cultures of human ovarian cystadenomas and LMP tumors and examination of their spectrum of expression of matrix-degrading proteinases. Gynecol Oncol 1997; 67: 277-284.
65. Yu J, Roy D, Dubeau L. Increased chromosomal stability of ovarian tumors of low malignant potential compared to cystadenomas. Br J Cancer 2007; 96: 1908-1913.
66. Velicescu M, Yu J, Herbert BS et al. Aneuploidy and telomere attrition are independent determinants of crisis in SV40-transformed epithelial cells. Cancer Res 2003; 63: 5813-5820.
67. Yu VM, Marion CM, Austria TM et al. Role of BRCA1 in controlling mitotic arrest in ovarian cystadenoma cells. Int J Cancer 2011; 130: 2495-2504.
68. Miyoshi I, Takahashi K, Kon Y et al. Mouse transgenic for murine oviduct-specific glycoprotein promoter-driven simian virus 40 large T-antigen: tumor formation and its hormonal regulation. Molec Reprod Dev 2002; 63: 168-176.
69. Pearce CL, Chung K, Pike MC et al. Increased ovarian cancer risk associated with menopausal estrogen therapy is reduced by adding a progestin. Cancer 2009; 115: 531-539.
70. Kim J, Coffey DM, Creighton CJ et al. High-grade serous ovarian cancer arises from fallopian tube in a mouse model. Proc Natl Acad Sci USA 2012; 109: 3921-3926.
71. Chodankar R, Kwang S, Sangiorgi F et al. Cell-Nonautonomous induction of ovarian and uterine serous cystadenomas in mice lacking a functional BRCA1 in ovarian granulosa cells. Curr Biol 2005; 15: 561-565.
72. Hong H, Yen H-Y, Brockmeyer A et al. Changes in the mouse estrus cycle in response to Brca1 inactivation suggest a potential link between risk factors for familial and sporadic ovarian cancer. Cancer Res 2010; 70: 221-228.
73. Yen HY, Gabet Y, Liu Y et al. Alterations in Brca1 expression in mouse ovarian granulosa cells have short-term and long-term consequences on estrogen responsive organs. Lab Invest 2012; 92: 802-811.